Armata Pharmaceuticals is set to host a key opinion leader (KOL) webinar on November 25th at 10:00 AM EST, focusing on the critical issue of *Staphylococcus aureus* (S. aureus) bacteremia and featuring a discussion on their investigational therapeutic, AP-SA02. The event, organized in collaboration with Jones Research, promises to offer valuable insights into the challenges and potential solutions in combating this life-threatening bloodstream infection.

Armata Pharmaceuticals, a clinical-stage biotechnology company traded on the NYSE American under the ticker symbol ARMP, is dedicated to pioneering the development of bacteriophage therapeutics. These therapies utilize naturally occurring viruses, called bacteriophages, that specifically target and kill bacteria. The company's unique approach focuses on creating high-purity, pathogen-specific bacteriophage treatments, offering a potential alternative to traditional antibiotics, especially in the face of growing antibiotic resistance.

The webinar will delve into the complexities of S. aureus bacteremia, a serious infection that occurs when the S. aureus bacteria enters the bloodstream. This condition can lead to severe complications, including sepsis, endocarditis (infection of the heart valves), and osteomyelitis (bone infection). Current treatment options often rely on antibiotics, but the increasing prevalence of antibiotic-resistant strains of S. aureus, such as methicillin-resistant S. aureus (MRSA), poses a significant threat to public health.

AP-SA02, Armata's investigational therapeutic, is designed to address this challenge. It utilizes a targeted bacteriophage cocktail specifically engineered to combat S. aureus infections. The webinar will likely explore the mechanism of action of AP-SA02, its potential benefits compared to traditional antibiotics, and the clinical development pathway for this promising therapy. Attendees can expect to hear expert opinions on the current treatment landscape for S. aureus bacteremia and the potential role of bacteriophage therapy in the future. The insights shared by the KOLs could prove invaluable for healthcare professionals, researchers, and investors interested in the fight against antibiotic-resistant infections. The event highlights Armata Pharmaceutical's commitment to advancing innovative solutions in the realm of infectious disease treatment.